Trial intelligence / Profile preview

rhGH for Growth Failure in Pediatric CKD

NCT00194961Phase 4Terminated

Sponsor
Weill Cornell Medicine
Modality
Hormone, rProtein (Recombinant Protein), Biologic
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of somatropin in Growth failure (FTT), sponsored by Weill Cornell Medicine. Primary endpoint: Biochemical/Metabolic and Immunologic Parameters in Relation to Body Composition at 6 months. Status: terminated.

02

Drugs

somatropin
03

Conditions

Growth failure (FTT)

Beyond the preview

Go deeper on NCT00194961.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00194961.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call